tradingkey.logo

Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer Patients

ReutersJan 22, 2026 2:21 PM

- Hoth Therapeutics Inc HOTH.O:

  • HOTH THERAPEUTICS DELIVERS 100% CLINICAL RESPONSE WITH ~50% REDUCTION IN DISEASE SEVERITY IN OPEN-LABEL PK COHORT OF EGFR-TREATED CANCER PATIENTS

  • HOTH THERAPEUTICS INC - HT-001 WELL TOLERATED WITH NO UNEXPECTED SAFETY SIGNALS

  • HOTH THERAPEUTICS INC - ADDITIONAL ENDPOINTS SHOW ~34% IMPROVEMENT IN ONCOLOGY TOXICITY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI